Phase I Study of Combination of SOM 230 Long Acting Release (LAR) + Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Pasireotide (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 28 Nov 2014 Status changed from active, no longer recruiting to completed.
- 10 Jul 2014 Planned End Date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 10 Jul 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History